Does β‑Blocker Use Increase Depression Risk?
While depression is often cited as an adverse effect of β-blocker use, there is limited evidence supporting this causal relationship.
While depression is often cited as an adverse effect of β-blocker use, there is limited evidence supporting this causal relationship.
The likelihood of help or harm, also known as the risk/benefit ratio, was found to be more favorable for lithium.
The analysis included 5 antiseizure medications (eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate) evaluated in 17 randomized clinical trials.
Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines.
The aim of the study was to assess the benefits and risks associated with various acute treatments for episodic migraine.
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
During the study, 50 migraine patients randomly received either topically applied timolol maleate ophthalmic solution, 0.5%, or placebo eyedrops.
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
A recent Morbidity and Mortality Weekly Report highlights the risks associated with use of over-the-counter products containing undeclared prescription ingredients as well as the importance of collaboration between various health departments and systems to ensure a prompt response to an outbreak.
The CDC has reported observing a significant increase in the number of meningococcal disease cases with isolates containing a blaROB-1 β-lactamase enzyme gene, conferring resistance to penicillin antibiotics and, in some cases, ciprofloxacin as well.